top of page

Verastem licenses Duvelisib from Infinity Pharmaceuticals for $28 million

Verastem and Infinity Pharmaceuticals have entered into a license agreement under which Verastem licensed exclusive worldwide rights to develop and commercialise Infinity’s oncology product candidate duvelisib.


READ MORE

source: http://www.europeanpharmaceuticalreview.com/45186/news/industry-news/verastem-infinity-duvelisib/

#Pharmanews

Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page